The good news (and, yes, Virginia, there is good news) is that physician meetings will become increasingly more important to the industry—this according to Joseph Palo, an adviser at PricewaterhouseCoopers.
More highly specialized and targeted pharmaceuticals will require more meetings—educational meetings to train highly skilled sales reps and informational meetings with thought leaders to discuss how the products will be used."Meetings," said Palo, "provide one of the great exchange venues for information, motivation, and collaboration. They offer a means for physicians to learn about changes in the industry and apply those changes so that all of us as patients can live better as a result."
As for the current state of meetings, Pharmaceutical Executive's special section, Physician Meetings, takes a look at the impact of the revised PhRMA code on healthcare conventions (see "Information, Education, and Talk Trump Free Pens"). Exhibit booths outfitted with the latest technology have become less like meet-and-greet venues and more like discussion areas, as well as effective marketing channels. In "Two Views From a Booth" (see "Two Views From Inside The Exhibition Booth") two pharma executives explain why.
Meetings that rely on KOLs (key opinion leaders) are critical to the successful development and marketing of a drug. What happens then when industry access to KOLs becomes limited (see "The Shrinking Pool")?
And finally, we offer here a quick look at the state of meetings and events so far this year, according to data from SDI's "Physician Meeting and Event Audit."
In the first six months of 2009: